Summary
Erythropoietin levels have been determined in 24 patients with different gynecologic malignancies, who were treated with cisplatinum and endoxan. A statistically highly significant decrease was demonstrated 2 h after starting treatment with a further significant decrease at 6 h. After 12 h the erythropoietin concentrations returned to values similar to those before treatment started.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Al-Khatti A, Veith RW, Papayannopoulou T, Fritsch EF, Goldwasser E (1987) Stimulation of fetal hemoglobin synthesis by Erythropoietin. N Engl J Med 317:415
Bray GL, Reaman GH (1988) Partial deficiency of erythropoietin (EPO) resulting from cisplatin (CPDD) mediated nephrotoxicity. Blood 72 (Suppl): 37a
Carnot P, Deflandre C (1906) Sur l'activité hémopoietique des differents organes au cours de la régéneration du sang. Comptes rendues hebd. des Séances de l'Acad Sci Paris 143:432
Erslev AJ (1953) Humoral regulation of red cell production. Blood 8:349
Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW (1987) Correction of the anemia of end-stage renal disease with recombinant human Erythropoietin. Results of a Combined Phase I and II Clinical Trial. N Engl J Med 316:73
Fischl M, Galpin JE, Levine JD et al. (1990) Recombinant human Erythropoietin for patients with aids treated with zidovudine. N Engl J Med 322:1488
Hashimi LA, Khalyl MF, Salem PA (1984) Supraventricular tachycardia. A probable complication of platinum treatment. Oncology 41:174
Jacobs K, Shoemaker C, Rudersdorf F et al. (1985) Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 313:806
Jacobson LO, Goldwasser E, Fried W, Placak IF (1957) The role of kidney in erythropoiesis. Nature 179:633
Ludwig H, Fritz E, Kotzmann H et al. (1990) Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 322:1693
Miller CB, Jones RJ, Pantadosi S et al. (1989) Decreased erythropoietin (EPO) response associated with the anemia of malignancy. Paper presented at American Society of Clinical Oncology Annual Meeting. San Francisco, CA: 1989 May 23
Miyake T, Kung CK-H, Goldwasser E (1977) Purification of human erythropoietin. J Biol Chem 252:558
Reissmann KR (1950) Studies on the mechanism of erythropoietin stimulation in parabiotic rats during hypoxia. Blood 5:372
Wieczorek L, Hirth P, Schöpe KB, Scigalla P, Kruger D (1989) Molekulare Biologie von Erythropoietin: Innovative Aspekte der klinischen Medizin. Springer, Berlin Heidelberg New York
Winearls CG, Oliver DO, Pippard MJ et al. (1986) Effect of human Erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet II:1175
Wood P, Nygaard S, Hrhushesky WJM (1988) Cisplatin-induced anemia is correctable with erythropoietin. Blood 72 (Suppl): 52a
Author information
Authors and Affiliations
Additional information
Dedicated to Prof. Dr. P. Dittrich in honour of his 65th anniversary
Rights and permissions
About this article
Cite this article
Lechner, W., Artner-Dworzak, E., Sölder, E. et al. Influence on erythropoietin levels of treatment with cisplatinum-endoxan. Arch Gynecol Obstet 252, 49–53 (1992). https://doi.org/10.1007/BF02389607
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02389607